Patents by Inventor Manfred Stangl

Manfred Stangl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220033779
    Abstract: A genetically modified mesenchymal stem cell including an exogenous nucleic acid including a Klotho encoding region operably linked to a promoter or promoter/enhancer combination, wherein the genetically modified mesenchymal stem cell exhibits increased Klotho expression compared to an unmodified mesenchymal stem cell. Also disclosed are methods of treating a patient including administering a therapeutically effective number of the genetically modified mesenchymal stem cells to the patient. The methods of treatment include treating the patient for a neurodegenerative disease; cancer; organ fibrosis; renal disease; age-related changes of organs or organ systems; to slow, reverse and/or inhibit aging; arteriosclerosis; dementia; diabetes mellitus; erectile dysfunction; autoimmune diseases or autoimmune-related diseases; an inflammatory disease of the lung and sepsis.
    Type: Application
    Filed: September 17, 2021
    Publication date: February 3, 2022
    Inventors: Christine Günther, Manfred Stangl, Felix Hermann
  • Publication number: 20200217841
    Abstract: The present invention is a kit for the determination of a neurodegenerative disease wherein separately from each other the content of kynurenine and kynurenic acid in a body fluid is determined and the quotient of the content of kynurenine to the content of kynurenic acid is calculated.
    Type: Application
    Filed: March 19, 2020
    Publication date: July 9, 2020
    Inventors: Manfred STANGL, Michael MARZINZIG, Dietmar ABENDROTH
  • Publication number: 20190086396
    Abstract: The present invention concerns an in vitro method for the determination of a neurodegenerative disease wherein separately from each other the content of kynurenine and kynurenic acid in a body fluid is determined and the quotient of the content of kynurenine to the content of kynurenic acid is calculated.
    Type: Application
    Filed: August 7, 2018
    Publication date: March 21, 2019
    Inventors: Manfred STANGL, Michael MARZINZIG, Dietmar ABENDROTH
  • Publication number: 20180037868
    Abstract: A genetically modified mesenchymal stem cell (MSC) includes an exogenous nucleic acid that includes a Klotho encoding region operably linked to a promoter or promoter/enhancer combination. The MSCs can be used for the treatment of cancer, organ fibrosis, renal failure, age-related changes of organs or organ systems, arteriosclerosis, and neurodegenerative diseases, such as Alzheimer's disease (AD), Multiple sclerosis (MS), Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease, and Schizophrenia, as well as dementia, diabetes mellitus, sepsis and autoimmune diseases and autoimmune-related diseases.
    Type: Application
    Filed: February 26, 2016
    Publication date: February 8, 2018
    Inventors: Christine Günther, Manfred Stangl, Felix Hermann